Quality Comes First

          

APAC MARKETS

We seek to advance highly specialised and scientifically valuable fields to elevate the standard of healthcare.

Discover more about Menarini Group

For over 30 years, Menarini has been driving research and development to deliver innovative and effective medicines and healthcare solutions for patients affected by serious health conditions.

Gain a single point of entry to all major APAC markets with a direct presence in 13 key markets.

Sharing your partnering idea

Leverage our omni-channel approach to grow your brand across Asia Pacific.

MARKETS

The healthcare sector in Asia Pacific is rapidly growing. As part of the world’s leading Italian biopharmaceutical company, Menarini AP has a strong presence in 13 key markets across the region.

As a partner of choice for numerous global healthcare companies, we engage in the entire pharmaceutical development lifecycle to tap growth opportunities and grow their brand footprint. In doing so, we also support healthcare professionals and patients with quality medical products and technology to raise standards and invigorate lives for tomorrow.

Our APAC Headquarters

A. MENARINI ASIA-PACIFIC HOLDINGS PTE LTD
A. MENARINI ASIA-PACIFIC PRIVATE LIMITED
A. MENARINI SINGAPORE PTE LTD
A. MENARINI BIOMARKERS SINGAPORE PTE LTD

30 Pasir Panjang Road,
Mapletree Business City,
#08-32 Singapore 117440
Tel: +65-6494-7200
Fax: +65-6999-1787

 

2023

2023

  • 2023 - 09 - 20

    European Commission Approves Menarini Group’s ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation

    Each year in Europe more than 550,000 patients are diagnosed with breast cancer, of whom 70% have estrogen receptor (ER)-positive disease¹; more than 147,000 breast cancer patients in Europe die annually from the disease²
  • 2023 - 09 - 13

    Menarini Asia-Pacific Enters into an Exclusive Licensing Agreement with Astellas to Commercialize Smyraf® in Taiwan and select South-East Asian markets

    SINGAPORE, Sept. 13, 2023 - Menarini Asia-Pacific has entered into a long-term exclusive licensing partnership with Astellas Pharma Inc. (Astellas) for the development, manufacturing and commercialization of the orally administered Janus kinase (JAK) inhibitor Smyraf® 50 mg and 100 mg Tablets (generic name: peficitinib hydrobromide) in Taiwan for the treatment of rheumatoid arthritis. Smyraf® has been approved in Taiwan and has patent protection for composition of matter until 2032.
  • 2023 - 07 - 21

    Menarini Group Receives Positive CHMP Opinion Recommending EC Approval of ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation

    Each year in Europe more than 550,000 patients are diagnosed with breast cancer, of whom 70% have estrogen receptor (ER)-positive disease¹; more than 147,000 breast cancer patients in Europe die annually from the disease²
  • 2023 - 07 - 06

    Fair Play Menarini International Awards, the champions of Fair Play cast their spell on the audience in Fiesole

    FLORENCE, July 6th, 2023 – Yesterday evening, the grand finale of the XXVII edition of the Menarini International Fair Play Awards was warmly greeted by over one thousand spectators at the Roman Theatre in Fiesole. The event, organised by the Menarini Fair Play Foundation and focused on the culture of fair play and respect in sport, drew to a close for the first time on this magnificent stage. Headlining the event were the winners of the 2023 edition, internationally renowned sports legends, shining examples of a healthy approach to competition, both in sporting events and life.
  • 2023 - 07 - 03

    Fair Play Menarini International Awards, the 2023 edition starts with the talk show “The Champions tell their Stories” in Piazza della Signoria, Florence

    FLORENCE, July 2, 2023 – The countdown has begun to the XXVII edition of the Fair Play Menarini International Awards. Tomorrow, Monday, July 3rd, the 2023 edition of the event, dedicated to the sporting values of ethics, fair play and respect, will officially begin in the city of Florence, with the eagerly-awaited talk show “The Champions tell their Stories”.
  • 2023 - 06 - 20

    Fair Play Menarini International Awards announces the winners of the XXVII edition at CONI

    ROME, June 19th, 2023 - The winners of the XXVII annual Fair Play Menarini International Awards are no longer a secret. This morning at the CONI Hall of Honour, a press conference was held to present the 2023 edition of the awards, scheduled from July 3rd to 5th in Florence and Fiesole.
  • 2023 - 05 - 16

    Menarini presents in Florence its latest art monograph, dedicated to the symbol of the Italian Renaissance.

    Successful artist, sensitive interpreter of the culture of his time and author of extraordinarily relevant works, Sandro Botticelli was a master of beauty. With his “Venuses,” he unknowingly established a canon of perfection that closely reflects that of modern day.
  • 2023 - 04 - 13

    The Dates of the XXVII Edition of the International Fair Play Menarini Awards

    FLORENCE, April 13, 2023 – Preparations are already underway for the International Fair Play Menarini Awards. This year, the event that pays tribute to athletes who demonstrate values such as ethics, loyalty and respect both in sport and in life, is in its XXVII edition and will host international sporting legends over the course of the three-day event in Florence and Fiesole.
  • 2023 - 01 - 30

    Stemline Therapeutics, a subsidiary of Menarini Group, Receives U.S. FDA Approval for ORSERDUTM (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer

    FLORENCE (Italy) and New York City (U.S.) January 30th, 2023 – The Menarini Group (“Menarini”), a leading Italian pharmaceutical and diagnostics company, announced today that the U.S. Food and Drug Administration (FDA) has approved ORSERDU for the treatment of postmenopausal women or adult men, with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. Stemline Therapeutics (“Stemline”), a wholly-owned subsidiary of the Menarini Group, headquartered in New York and focused on bringing transformational oncology treatments for cancer patients, will commercialize ORSERDU in the U.S.